However, more regulator genes negatively related to those compounds, like AGO2, DCP2, EIF3D, EIF4E, LARP1, and NCBP3 (related to 30 cancer drugs both in GDSC and CTRP), indicating the patients with higher mRNA expression level of these regulator genes might sensitive to these compounds. This evidence concerns the gene NCBP3 and cancer.